BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31395740)

  • 1.
    Mathsyaraja H; Freie B; Cheng PF; Babaeva E; Catchpole JT; Janssens D; Henikoff S; Eisenman RN
    Genes Dev; 2019 Sep; 33(17-18):1252-1264. PubMed ID: 31395740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mnt modulates Myc-driven lymphomagenesis.
    Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
    Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
    Link JM; Hurlin PJ
    Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycomb group ring finger protein 6 suppresses Myc-induced lymphomagenesis.
    Tanaskovic N; Dalsass M; Filipuzzi M; Ceccotti G; Verrecchia A; Nicoli P; Doni M; Olivero D; Pasini D; Koseki H; Sabò A; Bisso A; Amati B
    Life Sci Alliance; 2022 Aug; 5(8):. PubMed ID: 35422437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
    Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
    J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural aspects of interactions within the Myc/Max/Mad network.
    Nair SK; Burley SK
    Curr Top Microbiol Immunol; 2006; 302():123-43. PubMed ID: 16620027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myc suppression of Nfkb2 accelerates lymphomagenesis.
    Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
    BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.
    Diolaiti D; McFerrin L; Carroll PA; Eisenman RN
    Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding.
    Park S; Chung S; Kim KM; Jung KC; Park C; Hahm ER; Yang CH
    Biochim Biophys Acta; 2004 Feb; 1670(3):217-28. PubMed ID: 14980448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer.
    Venkateswaran N; Lafita-Navarro MC; Hao YH; Kilgore JA; Perez-Castro L; Braverman J; Borenstein-Auerbach N; Kim M; Lesner NP; Mishra P; Brabletz T; Shay JW; DeBerardinis RJ; Williams NS; Yilmaz OH; Conacci-Sorrell M
    Genes Dev; 2019 Sep; 33(17-18):1236-1251. PubMed ID: 31416966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
    Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
    Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis.
    Potts MA; Mizutani S; Garnham AL; Li Wai Suen CSN; Kueh AJ; Tai L; Pal M; Strasser A; Herold MJ
    Cell Death Differ; 2023 Jun; 30(6):1447-1456. PubMed ID: 36894688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max.
    Gu W; Cechova K; Tassi V; Dalla-Favera R
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2935-9. PubMed ID: 8385351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).
    Kyo S; Takakura M; Taira T; Kanaya T; Itoh H; Yutsudo M; Ariga H; Inoue M
    Nucleic Acids Res; 2000 Feb; 28(3):669-77. PubMed ID: 10637317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants.
    Mukherjee B; Morgenbesser SD; DePinho RA
    Genes Dev; 1992 Aug; 6(8):1480-92. PubMed ID: 1644290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
    Hurlin PJ; Quéva C; Eisenman RN
    Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.